MedTrace Logo

Phase 1 Study of L-NMMA in Patients With Liver Cirrhosis

NCT00344916 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2006-07-11

No results posted yet for this study

Summary

Phase 1 study of the effects of nitric oxide inhibition with L-NMMA in patients with liver cirrhosis and healthy controls. It is hypothesized that nitric oxide availability is increased in liver cirrhosis.

Conditions

Interventions

DRUG

Ng-monomethyl-L-arginine (drug)

Sponsors & Collaborators

  • Regional Hospital Holstebro

    lead OTHER

Principal Investigators

  • Erling B Pedersen, Professor · Dept. of Medicine, Holstebro Hospital, 7500 Holstebro, Denmark

  • Jesper N Bech, MD, Ph.d. · Dept. of Medicine, Holstebro Hospital, 7500 Holstebro, Denmark

Study Design

Allocation
RANDOMIZED
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00344916 on ClinicalTrials.gov